Articles related to Hematology

Are you one of those that makes a New Year’s Resolution, only to see it disappear by February? Don’t worry – you’re not alone. It’s not about making the list of what you want to achieve in the new year, it’s about “chunking” up that list into small, actionable, daily goals that you can achieve and feel. Read on to discover the habits you should be striving to make – and those you should be striving to break.

These evidence-based guidelines from the American Society of Hematology (ASH), the International Society on Thrombosis and Haemostasis (ISTH), the National Hemophilia Foundation (NHF), and the World Federation of Hemophilia (WFH) are intended to support patients, clinicians, and health care professionals in their decisions about management of von Willebrand Disease (VWD), a common inherited bleeding disorder.

In the two-and-a-half-hours of suggested physical activity every week, we should be getting 10 minutes of heart-pumping exercise into every session. But what about those who like to jog in the morning and those who love pumping the iron after work? Who is better off? If you believe a 2019 study, it really doesn’t matter – consistency is key if your end goal is weight loss.

The term abscopal effect (from Latin, ab, meaning “away from,” and scopus, meaning “target”) was coined in 1953, specifically referring to effects of ionizing radiation outside the radiated tumor volume. Does the evidence show that, contrary to widely held perception in the field, the abscopal effect is exceedingly rare and is not clinically relevant when using anti–PD-1/PD-L1 therapies and stereotactic body radiation therapy (SBRT) for head and neck cancer (HNC)?

From the pages of Clinical Advances in Hematology & Oncology comes this Q&A with Jennifer A. Woyach, MD, a Professor of Medicine in the Division of Hematology at the Ohio State University Comprehensive Cancer Center. Dr. Woyach provides extensive commentary on BTK, BCL2, and PI3K inhibitors, FCR usage, and the importance of clinical trials when treating patients with CLL.

Although initial animal studies indicated this drug might increase the risk of cancer, current research is showing the opposite. In a large systematic review and meta-analysis, for example, researchers showed that patients who took these drugs before their cancer diagnosis had a 21% lower risk of all-cause mortality and a 31% lower risk of cancer-specific mortality. What is it?